Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in the care of Lung Cancer patients in sub-Saharan Africa.

Lead Faculty: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist

Executive Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com

Website: www.intercancer.com

This educational activity is provided by the International Cancer Institute (ICI)

Faculty

1. Dr Sitna Mwanzi-Medical Oncologist
2. Dr Kibet Kibor Keitany– Anatomic Pathologist
3. Dr Zipporah Ali– Palliative Care Specialist
4. Gilbert Oburu-Cardiovascular & Thoracic Surgeon
5. Dr Nindhana Paranthaman-Senior Medical Scientist: Thoracic Oncology
6. Dr Helena Musau-Clinical Oncologist
7. Dr Abdu Adem Yesufe– Clinical Oncologist

This course will be accredited by:

Target Audience

The primary target audience for this course comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology PharmTechs; Oncology clinical officers; physician assistants; and other allied health care professionals,

Learning Objectives 

At the end of this educational activity, participants should be able to:

1. To learn about lung cancer data in Kenya and sub-Saharan Africa (SSA)
2. To learn about the evidence-base for lung cancer screening
3. To understand diagnostic modalities including the role of Biopsies / Re-Biopsies / Liquid Biopsy in Patients with NSCLC
4. To learn about the TNM staging and the different subtypes of NSCLC
5. To understand the different treatment strategies in NSCLC
6. To learn about the management of early-stage Non-Small-Cell Lung Cancer and the use of adjuvant treatments
7. To understand the role of multi-modality treatment in locally advanced NSCLC and limited-stage SCLC
8. To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC (Personalized Therapies)
9. To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
10. To learn about the systemic treatment of mesothelioma and SCLC
11. To learn about the role of supportive and palliative care for lung cancer

 Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labelled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

This activity is supported by an educational grant from Bristol Myers Squibb Foundation (BMSF).